These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 32078016)

  • 1. Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients.
    Wang QT; Nie Y; Sun SN; Lin T; Han RJ; Jiang J; Li Z; Li JQ; Xiao YP; Fan YY; Yuan XH; Zhang H; Zhao BB; Zeng M; Li SY; Liao HX; Zhang J; He YW
    Cancer Immunol Immunother; 2020 Jul; 69(7):1375-1387. PubMed ID: 32078016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I Trial of Intratumoral Injection of
    Lee JM; Lee MH; Garon E; Goldman JW; Salehi-Rad R; Baratelli FE; Schaue D; Wang G; Rosen F; Yanagawa J; Walser TC; Lin Y; Park SJ; Adams S; Marincola FM; Tumeh PC; Abtin F; Suh R; Reckamp KL; Lee G; Wallace WD; Lee S; Zeng G; Elashoff DA; Sharma S; Dubinett SM
    Clin Cancer Res; 2017 Aug; 23(16):4556-4568. PubMed ID: 28468947
    [No Abstract]   [Full Text] [Related]  

  • 3. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.
    Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL
    Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of tumor antigens and tumor-antigen specific T cells in NSCLC patients: Correlation of the quality of T cell responses with NSCLC subtype.
    Palata O; Podzimkova Hradilova N; Mysiková D; Kutna B; Mrazkova H; Lischke R; Spisek R; Adkins I
    Immunol Lett; 2020 Mar; 219():46-53. PubMed ID: 31931024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients.
    Aarntzen EH; Schreibelt G; Bol K; Lesterhuis WJ; Croockewit AJ; de Wilt JH; van Rossum MM; Blokx WA; Jacobs JF; Duiveman-de Boer T; Schuurhuis DH; Mus R; Thielemans K; de Vries IJ; Figdor CG; Punt CJ; Adema GJ
    Clin Cancer Res; 2012 Oct; 18(19):5460-70. PubMed ID: 22896657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma.
    Phuphanich S; Wheeler CJ; Rudnick JD; Mazer M; Wang H; Nuño MA; Richardson JE; Fan X; Ji J; Chu RM; Bender JG; Hawkins ES; Patil CG; Black KL; Yu JS
    Cancer Immunol Immunother; 2013 Jan; 62(1):125-35. PubMed ID: 22847020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.
    Aarntzen EH; De Vries IJ; Lesterhuis WJ; Schuurhuis D; Jacobs JF; Bol K; Schreibelt G; Mus R; De Wilt JH; Haanen JB; Schadendorf D; Croockewit A; Blokx WA; Van Rossum MM; Kwok WW; Adema GJ; Punt CJ; Figdor CG
    Cancer Res; 2013 Jan; 73(1):19-29. PubMed ID: 23087058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of dendritic cell-based vaccine using high hydrostatic pressure for non-small cell lung cancer immunotherapy.
    Hradilova N; Sadilkova L; Palata O; Mysikova D; Mrazkova H; Lischke R; Spisek R; Adkins I
    PLoS One; 2017; 12(2):e0171539. PubMed ID: 28187172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells.
    Hirschowitz EA; Foody T; Hidalgo GE; Yannelli JR
    Lung Cancer; 2007 Sep; 57(3):365-72. PubMed ID: 17509725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological markers of anti-tumor dendritic cells vaccine efficiency in patients with non-small cell lung cancer.
    Skachkova OV; Khranovska NM; Gorbach OI; Svergun NM; Sydor RI; Nikulina VV
    Exp Oncol; 2013 Jun; 35(2):109-13. PubMed ID: 23828386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.
    Jan CI; Tsai WC; Harn HJ; Shyu WC; Liu MC; Lu HM; Chiu SC; Cho DY
    Front Immunol; 2018; 9():727. PubMed ID: 29910795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of dendritic cell vaccines pulsed with Wilms' tumour-1 peptide antigen on the survival of patients with advanced non-small cell lung cancers.
    Takahashi H; Okamoto M; Shimodaira S; Tsujitani S; Nagaya M; Ishidao T; Kishimoto J; Yonemitsu Y;
    Eur J Cancer; 2013 Mar; 49(4):852-9. PubMed ID: 23245331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma.
    Butterfield LH; Vujanovic L; Santos PM; Maurer DM; Gambotto A; Lohr J; Li C; Waldman J; Chandran U; Lin Y; Lin H; Tawbi HA; Tarhini AA; Kirkwood JM
    J Immunother Cancer; 2019 Apr; 7(1):113. PubMed ID: 31014399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of autologous dendritic cell tumor vaccine in patients with non-small cell lung cancer.
    Um SJ; Choi YJ; Shin HJ; Son CH; Park YS; Roh MS; Kim YS; Kim YD; Lee SK; Jung MH; Lee MK; Son C; Choi PJ; Chung J; Kang CD; Lee EY
    Lung Cancer; 2010 Nov; 70(2):188-94. PubMed ID: 20223553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients.
    Mitchell DA; Batich KA; Gunn MD; Huang MN; Sanchez-Perez L; Nair SK; Congdon KL; Reap EA; Archer GE; Desjardins A; Friedman AH; Friedman HS; Herndon JE; Coan A; McLendon RE; Reardon DA; Vredenburgh JJ; Bigner DD; Sampson JH
    Nature; 2015 Mar; 519(7543):366-9. PubMed ID: 25762141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.
    Butterfield LH; Comin-Anduix B; Vujanovic L; Lee Y; Dissette VB; Yang JQ; Vu HT; Seja E; Oseguera DK; Potter DM; Glaspy JA; Economou JS; Ribas A
    J Immunother; 2008 Apr; 31(3):294-309. PubMed ID: 18317358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy.
    Fong L; Hou Y; Rivas A; Benike C; Yuen A; Fisher GA; Davis MM; Engleman EG
    Proc Natl Acad Sci U S A; 2001 Jul; 98(15):8809-14. PubMed ID: 11427731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs.
    Nakamura M; Iwahashi M; Nakamori M; Ueda K; Ojima T; Naka T; Ishida K; Yamaue H
    Oncology; 2005; 68(2-3):163-70. PubMed ID: 16006753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous dendritic cell vaccines for non-small-cell lung cancer.
    Hirschowitz EA; Foody T; Kryscio R; Dickson L; Sturgill J; Yannelli J
    J Clin Oncol; 2004 Jul; 22(14):2808-15. PubMed ID: 15254048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma.
    Sarivalasis A; Boudousquié C; Balint K; Stevenson BJ; Gannon PO; Iancu EM; Rossier L; Martin Lluesma S; Mathevet P; Sempoux C; Coukos G; Dafni U; Harari A; Bassani-Sternberg M; Kandalaft LE
    J Transl Med; 2019 Nov; 17(1):391. PubMed ID: 31771601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.